The causal relation between human papillomavirus and cervical cancer. Bosch, Xaver. Journal of clinical pathology, 28-11-2006, p 245.

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. J Pathol. 1999; 189(1):12-9)

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK et al. Lancet 1999;354:20-5. Updating the natural history of HPV and anogenital cancer. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Vaccine 24S3(2006)/S3/42-S3/51

"HPV-mediated cervical carcinogenesis: concepts and clinical implications." Snijders, P. J. et al. J Pathol. 208.2 (2006): 152-64.

Mythos krebsvorsage. Weymeyer, Christian, Koch, Klaus.. Echborn 2003. p 183.

Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Muñoz N, Bosch FX, Castellsague X, Diaz M, Sanjose S, Hammouda D, Shah KV, Meijer CJ, Int J Cancer 2004

Immune responses to human papillomavirus. Stanley M. Vaccine 2006b; 24 (Suppl. 1): 16 – 22.

HPV Prevalence Surveys Study Group Epidemiology Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, et al. The IARC Int J Cancer 2006 Sep 21;[Epub ahead of print]

Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women, (Rachel L. Winer, Ph.D., James P. Hughes, Ph.D., Qinghua Feng, Ph.D., Sandra O’Reilly, B.S., Nancy B. Kiviat, M.D., King K. Holmes, M.D., Ph.D., and Laura A. Koutsky, Ph.D. New England Journal of Medicine, Vol. 356, No. 19, May 10, 2007: 1991-1993

Overview of the European and North American trials on HPV testing in primary cervical screening.Cuzick J, Clavel C, Petry K-U, Meijer C, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P and Iftner T. Int J Cancer 2006; 119: 1095-1101.

Publicatie van de Hoge Gezondheidsraad nr 8204: Vaccinaties tegen infecties veroorzaakt door het human papillomavirus. N / 070329, 2 mei 2007.

NVIC: Analysis of Vaccine Adverse Events Reporting System Reports: Part III

Aluminum in large and small volume parenterals used in total parenteral nutrition. Federal Register/Rules and Regulations. §201.323 Vol 68 (106) Tuesday June 3, 2003. Page 32981

Aluminum adjuvant linked to Gulf War Illness induces motor neuron death in mice. MS Petrik, et cl. Neuromolecular Medicne 2007; 9(1):83-100.

LA Koutsky et al NEJM 2002. SL Block et al Pediatrics, 2006. GP Poland et al, Mayo Clinic Proceedings 2005. LLVilla et al, Lancet-Oncology 2005. C Mao et al. Obstetrics & Gynecology 2006.

Characterization and immunomodulating activities of polysaccharide from Lentinus edodes. Zheng R, Jie S, Hanchuan, Moucheng W. Int Immunopharmacol. 2005;5:811-820.

De FDA heeft het rapport van haar site gehaald, maar het is alsnog vastgelegd op: http://www.NewsTarget.com/downloads/FDA-HPV.pdf

Aneuploidie. Paradigmawechsel inder Krebstherapie.,Impfungen bei Gebarmutterhalskrebs. Eine neue Attack auf Patientinnen, Raum &Zeit, Hein Thomas 144/2006 s 11 Engelbrecht Torsten, , Co’Med, August 2005, s 30-35

Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. Lancet 2006;367(9518):1247-55

Diana Harper, in the Indiana based Daily news: http://www.fwdailynews.com/articles/2007/03/14/online_features/hpv_vaccine/hpv01.txt

HPV Vaccination - More Answers, More Questions. George F. Sawaya, M.D., and Karen Smith-McCune, M.D., Ph.D. New England Journal of Medicine, Vol. 356, No. 19, May 10, 2007: 1991-1993.